Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-2.87m
- Incorporated--
- Employees44.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttp://www.oryzon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AB Science SA | 970.00k | -10.05m | 108.84m | 89.00 | -- | -- | -- | 112.20 | -0.212 | -0.212 | 0.0193 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 60.52 | 88.41 | -1,034.95 | -1,120.00 | -- | -- | -- | -- | 1.25 | -10.63 | 26.20 | -- | -- | -- |
Maat Pharma SA | 2.23m | -19.72m | 109.79m | 50.00 | -- | 4.48 | -- | 49.28 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
Scancell Holdings Plc | 0.00 | -13.30m | 110.13m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
Arcticzymes Technologies ASA | 10.16m | 1.45m | 110.58m | 61.00 | 76.33 | 4.09 | 55.33 | 10.89 | 0.3302 | 0.3302 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | -- | 5.10 | 15.52 | 5.44 | 17.16 | 95.50 | 96.69 | 14.31 | 33.10 | 12.14 | -- | 0.0327 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
Malin Corporation plc | 0.00 | 0.00 | 110.95m | 3.00 | -- | 1.02 | 554.77 | -- | -0.0154 | -0.0154 | 0.00 | 5.77 | 0.00 | -- | -- | 0.00 | 0.00 | 7.09 | 0.00 | 7.66 | -- | -- | -- | 273.93 | -- | -- | 0.00 | 0.00 | -- | -- | -100.00 | -- | -- | -- |
Medica SpA | 63.83m | 3.26m | 111.49m | 706.00 | 34.17 | 2.26 | 11.48 | 1.75 | 0.7727 | 0.7727 | 15.11 | 11.68 | 0.5817 | 1.07 | 5.22 | 90,672.33 | 2.26 | -- | 3.31 | -- | 58.28 | -- | 3.88 | -- | 0.8276 | 4.21 | 0.3487 | -- | 16.13 | -- | -12.52 | -- | -- | -- |
Scope Fluidics SA | 120.87k | -4.40m | 118.76m | 40.00 | -- | 6.26 | -- | 982.60 | -6.89 | -6.89 | 0.1893 | 29.69 | 0.0023 | 2.73 | 0.1827 | 12,900.00 | -8.39 | 52.74 | -8.61 | 57.32 | -265.89 | -420.87 | -3,640.50 | 30,134.78 | 14.60 | -- | 0.0289 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
Santhera Pharmaceuticals Holding AG | 104.30m | 55.27m | 119.22m | 46.00 | -- | 1.75 | -- | 1.14 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
DBV Technologies SA | 14.53m | -67.19m | 123.23m | 104.00 | -- | 0.948 | -- | 8.48 | -0.7082 | -0.7082 | 0.1528 | 1.35 | 0.0732 | -- | 1.18 | 139,756.90 | -33.86 | -53.18 | -40.10 | -65.47 | -- | 93.62 | -462.30 | -1,145.92 | -- | -- | 0.0388 | -- | 224.69 | -1.71 | 24.27 | -- | -34.47 | -- |
Oryzon Genomics SA | 0.00 | -2.87m | 123.55m | 44.00 | -- | 1.46 | -- | -- | -0.0431 | -0.0431 | 0.00 | 1.34 | 0.00 | 101.09 | -- | 0.00 | -2.72 | -4.20 | -3.19 | -4.82 | -- | -- | -- | -- | 0.8741 | -3.16 | 0.1487 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
Molecular Partners AG | 6.79m | -59.05m | 124.54m | 168.00 | -- | 0.6562 | -- | 18.35 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
Transgene SA | 7.63m | -22.33m | 132.32m | 158.00 | -- | 8.45 | -- | 17.33 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Adocia SA | 2.15m | -21.16m | 132.61m | 78.00 | -- | -- | -- | 61.68 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
Photocure ASA | 44.20m | 354.51k | 135.45m | 106.00 | 388.72 | 3.25 | 48.44 | 3.06 | 0.149 | 0.149 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | -- | 0.5786 | -3.09 | 0.6548 | -3.56 | 94.65 | 93.64 | 0.802 | -5.19 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
Heidelberg Pharma AG | 9.05m | -18.28m | 138.42m | 98.00 | -- | 3.07 | -- | 15.29 | -0.3957 | -0.3957 | 0.196 | 0.968 | 0.1222 | 0.2187 | 11.87 | 95,273.69 | -24.68 | -43.91 | -33.18 | -64.34 | 79.75 | 52.13 | -201.94 | -206.24 | 2.22 | -- | 0.104 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
Holder | Shares | % Held |
---|---|---|
SSgA Funds Management, Inc.as of 09 May 2024 | 137.02k | 0.22% |
Dimensional Fund Advisors LPas of 09 May 2024 | 90.29k | 0.15% |
Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 50.00k | 0.08% |
Gescooperativo SA SGIICas of 31 Dec 2023 | 47.91k | 0.08% |
Tressis Gesti�n SGIIC SAas of 31 Dec 2023 | 45.00k | 0.07% |
Solventis SGIIC SAas of 31 Dec 2023 | 20.00k | 0.03% |
Dimensional Fund Advisors Ltd.as of 09 May 2024 | 12.54k | 0.02% |
Gesiuris Asset Management SGIIC SAas of 31 Dec 2023 | 8.00k | 0.01% |
Gesti�n de Patrimonios Mobiliarios AV SAas of 31 Mar 2024 | 6.00k | 0.01% |
Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 200.00 | 0.00% |